Vancouver, BC – Michael Abrams, president and CEO of biopharma company AnorMED, is the recipient of the Society of Chemical Industry’s (SCI) 2006 Julia Levy Award. The award recognizes successful innovation in Canada in the field of bio-medical science and engineering.
“I am honoured to receive this award,” said Dr Abrams, “not only for the acknowledgement of the accomplishments of AnorMED, but also for being regarded as possessing the same skills and talents as Julia Levy.”
Dr Abrams was chosen for the award in recognition of his critical involvement in the development of platinum-based cancer chemotherapeutic drugs leading to NX473, and a novel phosphate binder; as well as the development of an extensive product pipeline that includes a stem cell transplant product and an HIV entry inhibitor.
Established in London in 1881 and in New York in 1894, SCI is an international interdisciplinary organization, with membership in over 70 countries from diverse branches of science and sectors of science-related business. It exists to improve the exchange of information and understanding between researchers, industrialists, consumers, financiers and academics.